Pediatric Nephrology

, Volume 21, Issue 8, pp 1206–1208 | Cite as

Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing

  • Guido FillerEmail author
  • Anita Lathia
  • Claire LeBlanc
  • Uwe Christians
Brief Report


Enteric-coated mycophenolate sodium (EC-MPS) has a mean half-life of 11.7 hours, which encouraged hope of using this drug once daily in a nonadherent adolescent SLE patient. This is a case report on a 17-year-old adolescent with a history of noncompliance who was switched from twice-daily mycophenolate mofetil (MMF) to once-daily EC-MPS. The EC-MPS dose was equimolar to the daily MMF dose (1 g MMF BID and 1.44 g of EC-MPS OD). The active compound of both drugs, mycophenolic acid, was measured using a commercially available EMIT assay. Both drugs were well-tolerated and maintained remission of the SLE. The average of three 12-hour areas under the time–concentration curves (AUC) on 1 g of MMF BID was 59.0 mg×h/L. In contrast, the 24-hour AUC after 1.44 g EC-MPS OD was 283.2 mg×h/L, more than double the expected 118.0 mg×h/L of two MMF dosing intervals. A repeat 24-hour AUC after 1.08 g of EC-MPS was 218.2 mg×h/L. EC-MPS once daily may be a well-tolerated therapeutic option for nonadherent adolescent lupus patients, but may be associated with a significantly higher exposure than the equivalent MMF BID dose.


EC-MPS Mycophenolate sodium MMF Mycophenolic acid Systemic lupus erythematosus 


  1. 1.
    Li L, Wang H, Lin S, Chen X, Chen Y, Xu J, Chen N, Li X, Qian J, Hu W (2002) Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicentre clinical trial in China. Zhonghua Nei Ke Za Zhi 41:476–479PubMedGoogle Scholar
  2. 2.
    Spetie DN, Tang Y, Rovin BH, Nadasdy T, Nadasdy G, Pesavento TE, Hebert LA (2004) Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 66:2411–24159CrossRefGoogle Scholar
  3. 3.
    Pisoni CN, Karim Y, Cuadrado MJ (2005) Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 14(Suppl 1):s9–s11CrossRefGoogle Scholar
  4. 4.
    Filler G, Hansen M, LeBlanc C, Lepage N, Franke D, Mai I, Feber J (2003) Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 18:445–449CrossRefGoogle Scholar
  5. 5.
    Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, Maca J, Hall M, The ERL B301 Study Groups (2004) Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4:231–236CrossRefGoogle Scholar
  6. 6.
    Behrend M, Braun F (2005) Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs 65:1037–1050CrossRefGoogle Scholar
  7. 7.
    Budde K, Glander P, Diekmann F, Waiser J, Fritsche L, Dragun D, Neumayer HH (2004) Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 5:1333–1345CrossRefGoogle Scholar
  8. 8.
    Schutz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, Tonshoff B, Pethig K, Wahlers T, Braun F, Ringe B, Oellerich M (1998) Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 30:1185–1187CrossRefGoogle Scholar
  9. 9.
    Salvadori M, ERLB301 Study Group (2001) Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients. Transplant Proc 33:3245–3247CrossRefGoogle Scholar
  10. 10.
    Ettenger R, Bartosh S, Choi L, Zhu W, Niederberger W, Campestrini J, Bastien MC, Schmouder R (2005) Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant 9:780–787CrossRefGoogle Scholar
  11. 11.
    Gabardi S, Tran JL, Clarkson MR (2003) Enteric-coated mycophenolate sodium. Ann Pharmacother 37:1685–1693CrossRefGoogle Scholar
  12. 12.
    Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, van Gelder T (2005) Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5:987–994CrossRefGoogle Scholar
  13. 13.
    Christians U, Strom T, Zhang YL, Steudel W, Schmitz V, Trump S, Haschke M (2006) Active drug transport of immunosuppressants. New insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 28:39–44CrossRefGoogle Scholar
  14. 14.
    Sugioka N, Koyama H, Ohta T, Kishimoto H, Yasumura T, Takada K (1996) Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. J Pharm Sci 85:335–338CrossRefGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Guido Filler
    • 1
    Email author
  • Anita Lathia
    • 1
  • Claire LeBlanc
    • 2
  • Uwe Christians
    • 3
  1. 1.Division of Nephrology, Children’s Hospital of Eastern OntarioUniversity of OttawaOttawaCanada
  2. 2.Division of Rheumatology, Department of PediatricsChildren’s Hospital of Eastern OntarioOttawaCanada
  3. 3.Department of AnesthesiologyUniversity of Colorado Health Science CenterDenverUSA

Personalised recommendations